Cargando…
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...
Autores principales: | Lui, Austin, Vanleuven, Jordan, Perekopskiy, David, Liu, Dewey, Xu, Desiree, Alzayat, Omar, Elgokhy, Taiseer, Do, Timothy, Gann, Meghan, Martin, Ryan, Liu, Da-Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784968/ https://www.ncbi.nlm.nih.gov/pubmed/36558997 http://dx.doi.org/10.3390/ph15121546 |
Ejemplares similares
-
Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders
por: Lui, Austin, et al.
Publicado: (2022) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016) -
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021) -
Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
por: Zhu, Yan, et al.
Publicado: (2022)